Takeshi Ouchi

Dr. Takeshi Ouchi


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2021 in Cells
Verified
Journal Article
Open access
PDF file
TOTakeshi Ouchi
Takeshi Ouchi
SMSohshi Morimura
Sohshi Morimura
LDLukas E. Dow
Lukas E. Dow
HMHiroyuki Miyoshi
Hiroyuki Miyoshi
MUMark C Udey
Mark C Udey
Humans with biallelic inactivating mutations in Epithelial Cell Adhesion Molecule (EpCAM) develop congenital tufting enteropathy (CTE). To gain mechanistic insights regarding EpCAM function in this disorder, we prepared intestinal epithelial cell (IEC) organoids and spheroids. IEC organoids and spheroids were generated from ROSA-CreERT2 EpCAMfl/fl mice. Proliferation, tight junctions, cell polarity and epithelial integrity were assessed in tamoxifen-induced EpCAM-deficient organoids via confocal immunofluorescence microscopy and Western blotting. Olfm4-expressing stem cells were assessed in IEC cells in vitro and in vivo via fluorescence in situ hybridization. To determine if existing drugs could ameliorate effects of EpCAM deficiency in IEC cells, a variety of pharmacologic inhibitors were screened. Deletion of EpCAM resulted in increased apoptosis and attenuated growth of organoids and spheroids. Selected claudins were destabilized and epithelial integrity was severely compromised. Epithelial integrity was improved by treatment with Rho-associated coiled-coil kinase (ROCK) inhibitors without restoration of claudin expression. Correspondingly, enhanced phosphorylation of myosin light chain, a serine/threonine ROCK substrate, was observed in EpCAM-deficient organoids. Strikingly, frequencies of Olfm4-expressing stem cells in EpCAM-deficient IEC cells in vitro and in vivo were decreased. Treatment with ROCK inhibitors increased numbers of stem cells in EpCAM-deficient organoids and spheroids. Thus, EpCAM regulates intestinal epithelial homeostasis via a signaling pathway that includes ROCK.

12 March 2019 in The Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
KKKenta Kobayashi
Kenta Kobayashi
YKYuichi Kurihara
Yuichi Kurihara
JYJun Yamagami
Jun Yamagami
JIJumpei Ito
Jumpei Ito
HSHaruko Shima
Haruko Shima
TOTakeshi Ouchi
Takeshi Ouchi

2 May 2019 in Journal of Patient-Reported Outcomes
Verified
Journal Article
Open access
PDF file
KYKaori Yagasaki
Kaori Yagasaki
HTHayato Takahashi
Hayato Takahashi
TOTakeshi Ouchi
Takeshi Ouchi
JYJun Yamagami
Jun Yamagami
YHYasuo Hamamoto
Yasuo Hamamoto
HKHiroko Komatsu
Hiroko Komatsu
With the increased use of targeted therapies in oncology, dermatological adverse events (dAEs) have drawn attention. Because the face is crucial for human identity and social interactions, facial dAEs have significant impact on a patient’s quality of life. This study aimed to explore patients’ experience with regard to the management of targeted oncological therapy-induced facial dAEs. In this qualitative study, 20 patients at a university hospital in Japan with advanced/metastatic cancer and targeted therapy-induced facial dAEs were individually interviewed to collect data. Thematic analysis was used to analyze the data. Patients with cancer and targeted oncological therapy-induced facial dAEs who were referred to the Department of Dermatology had certain expectations from specialist services. Three key themes were identified: professional input and advice, empathetic commitment to individual management, and integrated care across specialties. The referred patients with cancer and facial dAEs needed more in-depth information and advice from dermatological services and were reassured by the empathetic commitment to individual management in integrated care across specialties. These findings suggest that attention to the patient’s perspective with a “sick person first” attitude and a collaborative effort across different specialties is important to minimize the effects of facial dAEs on the quality of life of patients with cancer.

6 September 2022
Verified
Conference Paper
Closed access
RTRyo Tanaka
Ryo Tanaka
YKYuichi Kurihara
Yuichi Kurihara
TOTakeshi Ouchi
Takeshi Ouchi
TFTakeru Funakoshi
Takeru Funakoshi
HTHayato Takahashi
Hayato Takahashi
JYJun Yamagami
Jun Yamagami
Current guidelines recommend that the disease severity and treatment efficacy should be evaluated with clinical scores in pemphigus/pemphigoid. P | POSTER